Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
The Journal of Antimicrobial Chemotherapy|February 17, 2025
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniaeMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Expert Review of Anti-Infective Therapy|April 1, 2025
Management of methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges aheadAlberto Enrico Maraolo, Milo Gatti, Luigi Principe, et al.
Journal of Critical Care|April 14, 2023
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)Milo Gatti, Matteo Rinaldi, Paolo Gaibani, et al.
The Journal of Antimicrobial Chemotherapy|August 19, 2024
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patientsPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Microorganisms|July 27, 2024
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCTMilo Gatti, Caterina Campoli, Edoardo Muratore, et al.
Journal of Global Antimicrobial Resistance|October 28, 2021
A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocolMilo Gatti, Michele Bartoletti, Pier Giorgio Cojutti, et al.
Microorganisms|January 21, 2022
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two CasesMilo Gatti, Giulio Virgili, Pier Giorgio Cojutti, et al.
Therapeutic Drug Monitoring|March 28, 2022
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological MalignanciesMilo Gatti, Caterina Campoli, Tamara Belotti, et al.
International Journal of Antimicrobial Agents|November 19, 2023
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infectionsPier Giorgio Cojutti, Milo Gatti, Nieko Punt, et al.
Infectious Disease Reports|February 24, 2022
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug MonitoringPier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
The Journal of Antimicrobial Chemotherapy|February 17, 2025
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniaeMilo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Expert Review of Anti-Infective Therapy|April 1, 2025
Management of methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges aheadAlberto Enrico Maraolo, Milo Gatti, Luigi Principe, et al.
Journal of Critical Care|April 14, 2023
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)Milo Gatti, Matteo Rinaldi, Paolo Gaibani, et al.
The Journal of Antimicrobial Chemotherapy|August 19, 2024
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patientsPier Giorgio Cojutti, Manjunath P Pai, Milo Gatti, et al.
Microorganisms|July 27, 2024
Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCTMilo Gatti, Caterina Campoli, Edoardo Muratore, et al.
Journal of Global Antimicrobial Resistance|October 28, 2021
A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocolMilo Gatti, Michele Bartoletti, Pier Giorgio Cojutti, et al.
Microorganisms|January 21, 2022
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two CasesMilo Gatti, Giulio Virgili, Pier Giorgio Cojutti, et al.
Therapeutic Drug Monitoring|March 28, 2022
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological MalignanciesMilo Gatti, Caterina Campoli, Tamara Belotti, et al.
International Journal of Antimicrobial Agents|November 19, 2023
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infectionsPier Giorgio Cojutti, Milo Gatti, Nieko Punt, et al.
Infectious Disease Reports|February 24, 2022
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug MonitoringPier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, et al.
Pageof 17